JPRN-UMIN000035002Completed未知
A retrospective cohort study to investigate the incidence of cachexia in colorectal cancer patients - A retrospective cohort study to investigate the incidence of cachexia in colorectal cancer patients
ONO PHARMACEUTICAL CO., LTD.0 sites150 target enrollmentStarted: November 27, 2018Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 150
Study Overview
Brief Summary
Cumulative incidence of cancer cachexia was 50.7% at 24 weeks, and reached 91.3% over the whole study period. OS was significantly different between patients with and without cancer cachexia within 24 weeks after starting first-line treatment, although the onset of cancer cachexia within 24 weeks could not be considered as an independent prognostic factor for OS. Severe appetite loss and fatigue tended to occur more frequently in patients with cancer cachexia within 24 weeks.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who meet at least one of the following exclusion criteria are not included. 1) Patients who underwent surgical operation of the gastrointestinal tract within the last 6 months, excluding colostomy and stent placement in the gastrointestinal tract 2) Patients with weight loss distinctly caused by a gastrointestinal transit disorder 3) Patients with simultaneously active, double cancer (Stage I intraepithelial carcinoma, intramucosal carcinoma, superficial bladder carcinoma, or other cancers without recurrence for 5 years or more can be registered) 4) Patients with missing of weight data over 12 weeks at the time of visit and during the subsequent medical consultation period 5) Patients who underwent puncture for ascitic fluid at the beginning of initial systemic chemotherapy
Investigators
Similar Trials
Completed
Not Applicable
A retrospective cohort study to investigate the incidence of cachexia in gastric cancer patientsGastric CancerJPRN-UMIN000033693ONO PHARMACEUTICAL CO., LTD.131
Completed
Not Applicable
A retrospective cohort study to investigate the incidence of cachexia in pancreatic cancer patientsPancreatic CancerJPRN-UMIN000034972ONO PHARMACEUTICAL CO., LTD.150
Completed
Not Applicable
Prospective observational study of cancer-cachexia and its effect on chemotherapy in patients with previously-untreated advanced non-small cell lung cancer (NEJ050A)on-small cell lung cancerJPRN-UMIN000041813orth East Japan Study Group (NEJSG)186
Completed
Not Applicable
Retrospective analysis of complete remission in cases with advanced non-small cell lung cancerJPRN-UMIN000037078Respiratory Division, Department of Internal Medicine, Tokai University School of Medicine443
Completed
Not Applicable
Post-marketing, prospective and non-randomized trial regarding to daclatasvir and asunaprevir combination therapy for chronic liver disease with genotype 1 hepatitis C virusChronic liver disease with hepatitis C virus (chronic hepatitis and compensated cirrhosis)JPRN-UMIN000025487Iwate medical university182